Mult Scler Relat Disord:托珠单抗治疗MOG-抗体谱系无效的病例报告

2018-11-30 MedSci MedSci原创

意大利热那亚大学眼科的Novi G等人近日在Mult Scler Relat Disord报告了一例病例,他们使用托珠单抗治疗髓磷脂少突胶质细胞糖蛋白抗体相关谱系障碍,病情得到缓解。

意大利热那亚大学眼科的Novi G等人近日在Mult Scler Relat Disord报告了一例病例,他们使用托珠单抗治疗髓磷脂少突胶质细胞糖蛋白抗体相关谱系障碍,病情得到缓解。

髓磷脂少突胶质细胞糖蛋白抗体相关谱系障碍(MOG-SD)是一种中枢神经系统的炎性脱髓鞘疾病,通常常规的免疫抑制疗法对其有一定的治疗效果。然而,对于治疗没有效果的患者原因知之甚少。

他们报告了一名20岁的MOG-SD患者病例,该患者使用利妥昔单抗来抑制B细胞,但患者仍然出现临床恶化的状况。

他们使用托珠单抗(TCZ)进行抢救治疗,这可防止进一步复发。MRI检测发现,脊髓负荷减少。两年后随访发现,病情得到显着缓解。

因此,他们的观察结果表明,TCZ可以改善临床放射学的治疗效果,这使其成为治疗MOG-SD的一种选择。

原文出处:

Novi, G., et al., Tocilizumab in MOG-antibody spectrum disorder: a case report. Mult Scler Relat Disord, 2018. 27: p. 312-314.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2041187, encodeId=6d90204118e5a, content=<a href='/topic/show?id=73f255210a0' target=_blank style='color:#2F92EE;'>#抗体谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55210, encryptionId=73f255210a0, topicName=抗体谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 18 19:32:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784407, encodeId=76511e8440700, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Apr 03 07:32:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012868, encodeId=9a0820128680c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed May 22 06:32:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377011, encodeId=480d13e7011a4, content=<a href='/topic/show?id=8ff8e0777c5' target=_blank style='color:#2F92EE;'>#病例报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70777, encryptionId=8ff8e0777c5, topicName=病例报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Dec 02 14:32:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585382, encodeId=c3d6158538282, content=<a href='/topic/show?id=2e681208016' target=_blank style='color:#2F92EE;'>#MOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12080, encryptionId=2e681208016, topicName=MOG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a85417178370, createdName=Boyinsh, createdTime=Sun Dec 02 14:32:00 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2041187, encodeId=6d90204118e5a, content=<a href='/topic/show?id=73f255210a0' target=_blank style='color:#2F92EE;'>#抗体谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55210, encryptionId=73f255210a0, topicName=抗体谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 18 19:32:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784407, encodeId=76511e8440700, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Apr 03 07:32:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012868, encodeId=9a0820128680c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed May 22 06:32:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377011, encodeId=480d13e7011a4, content=<a href='/topic/show?id=8ff8e0777c5' target=_blank style='color:#2F92EE;'>#病例报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70777, encryptionId=8ff8e0777c5, topicName=病例报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Dec 02 14:32:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585382, encodeId=c3d6158538282, content=<a href='/topic/show?id=2e681208016' target=_blank style='color:#2F92EE;'>#MOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12080, encryptionId=2e681208016, topicName=MOG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a85417178370, createdName=Boyinsh, createdTime=Sun Dec 02 14:32:00 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
    2019-04-03 cmsvly
  3. [GetPortalCommentsPageByObjectIdResponse(id=2041187, encodeId=6d90204118e5a, content=<a href='/topic/show?id=73f255210a0' target=_blank style='color:#2F92EE;'>#抗体谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55210, encryptionId=73f255210a0, topicName=抗体谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 18 19:32:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784407, encodeId=76511e8440700, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Apr 03 07:32:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012868, encodeId=9a0820128680c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed May 22 06:32:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377011, encodeId=480d13e7011a4, content=<a href='/topic/show?id=8ff8e0777c5' target=_blank style='color:#2F92EE;'>#病例报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70777, encryptionId=8ff8e0777c5, topicName=病例报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Dec 02 14:32:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585382, encodeId=c3d6158538282, content=<a href='/topic/show?id=2e681208016' target=_blank style='color:#2F92EE;'>#MOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12080, encryptionId=2e681208016, topicName=MOG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a85417178370, createdName=Boyinsh, createdTime=Sun Dec 02 14:32:00 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2041187, encodeId=6d90204118e5a, content=<a href='/topic/show?id=73f255210a0' target=_blank style='color:#2F92EE;'>#抗体谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55210, encryptionId=73f255210a0, topicName=抗体谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 18 19:32:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784407, encodeId=76511e8440700, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Apr 03 07:32:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012868, encodeId=9a0820128680c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed May 22 06:32:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377011, encodeId=480d13e7011a4, content=<a href='/topic/show?id=8ff8e0777c5' target=_blank style='color:#2F92EE;'>#病例报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70777, encryptionId=8ff8e0777c5, topicName=病例报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Dec 02 14:32:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585382, encodeId=c3d6158538282, content=<a href='/topic/show?id=2e681208016' target=_blank style='color:#2F92EE;'>#MOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12080, encryptionId=2e681208016, topicName=MOG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a85417178370, createdName=Boyinsh, createdTime=Sun Dec 02 14:32:00 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2041187, encodeId=6d90204118e5a, content=<a href='/topic/show?id=73f255210a0' target=_blank style='color:#2F92EE;'>#抗体谱#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55210, encryptionId=73f255210a0, topicName=抗体谱)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Apr 18 19:32:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1784407, encodeId=76511e8440700, content=<a href='/topic/show?id=a727600194' target=_blank style='color:#2F92EE;'>#Disord#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6001, encryptionId=a727600194, topicName=Disord)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aad0444, createdName=cmsvly, createdTime=Wed Apr 03 07:32:00 CST 2019, time=2019-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012868, encodeId=9a0820128680c, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed May 22 06:32:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1377011, encodeId=480d13e7011a4, content=<a href='/topic/show?id=8ff8e0777c5' target=_blank style='color:#2F92EE;'>#病例报告#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70777, encryptionId=8ff8e0777c5, topicName=病例报告)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8143398, createdName=lily1616, createdTime=Sun Dec 02 14:32:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585382, encodeId=c3d6158538282, content=<a href='/topic/show?id=2e681208016' target=_blank style='color:#2F92EE;'>#MOG#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12080, encryptionId=2e681208016, topicName=MOG)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a85417178370, createdName=Boyinsh, createdTime=Sun Dec 02 14:32:00 CST 2018, time=2018-12-02, status=1, ipAttribution=)]
    2018-12-02 Boyinsh

相关资讯

Ann Rheum Dis:托珠单抗与TNFi单药或与常规DMARDs联合治疗类风湿性关节炎的疗效比较

对于至少一种bDMARD疗效不佳的患者,TCZ单药或联合用药是合理的治疗选择,而TNFi联合治疗的药物滞留时间更长且疗效相似。

Clin Exp Rheumatol:托珠单抗可以调节类风湿性关节炎患者的血清脂联素和趋化素水平

TCZ能够调节RA患者的血清趋化素和脂联素水平,并与疾病治疗反应无关,这有助于解释TCZ的CV安全性。

PLos One:TNF抑制剂和托珠单抗对类风湿性关节炎糖化血红蛋白水平的影响

开始TNFi或TCZ治疗后,RA患者的HbA1c水平显著降低。这项研究表明TCZ降低RA患者HbA1c水平的程度大于TNFi。

J Rheumatol:托珠单抗治疗多关节型幼年特发性关节炎期间的生长情况:III期临床试验数据

基线Tanner分期≤3的pcJIA患者中,72%(74/103)在研究结束时身高SDS升高。

Ann Rheum Dis:类风湿性关节炎患者托珠单抗或联合甲氨蝶呤治疗缓解后的托珠单抗停药

在一半以上的患者中,托珠单抗停药后的持续低疾病活动性可以通过继续使用甲氨喋呤得到维持。重新使用托珠单抗使超过90%的患者得到缓解。

Ann Rheum Dis :托珠单抗对糖皮质激素难治性成人still病的疗效

该研究表明,尽管未达到主要终点,并且没有得出可靠的结论,托珠单抗治疗成人Still病是有效的。